Abstract
Recombinant vesicular stomatitis virus (VSV) is a promising therapeutic vaccine platform. Using a transgenic mouse model of chronic hepatitis B virus (HBV) infection, we evaluated the therapeutic potential of a VSV vector expressing the HBV middle surface envelope glycoprotein (MS). VSV-MS immunization generated HBV-specific CD8 T cell and antibody responses in transgenic mice that express low HBV antigen levels. These findings support the further development of VSV as a therapeutic vaccine vector for chronic HBV.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
CD8-Positive T-Lymphocytes / immunology*
-
Hepatitis B / immunology
-
Hepatitis B / therapy*
-
Hepatitis B Surface Antigens / immunology
-
Hepatitis B Vaccines / immunology*
-
Hepatitis B virus / immunology*
-
Mice
-
Mice, Transgenic
-
Vesicular stomatitis Indiana virus / immunology*
-
Viral Envelope Proteins / immunology*
Substances
-
Hepatitis B Surface Antigens
-
Hepatitis B Vaccines
-
Viral Envelope Proteins
-
middle envelope protein, Hepatitis B virus